The company has been pushing for more reimbursement of its three marketed DTx products in the US following a first FDA approval in 2017.
Pear said that the Ohio Department of Mental Health and Addiction Services (OhioMHAS) and RecoveryOhio are providing access to Pear’s FDA-approved DTx reSET and reSET‑O, for treatment of substance use disorder and opioid use disorders, respectively. [Read more…] about Ohio joins Indiana and Kentucky in funding Pear Therapeutics’ digital addiction treatments
substance use disorder
“Boston- and San Francisco-based Pear Therapeutics, maker of a prescription digital therapeutic platform, announced today the closure of $50 million in Series B funding. The round was led by Singapore-based investment company Temasek, with participation from returning investors 5AM Ventures, Arboretum Ventures, and JAZZ Venture Partners, as well as new partners Novartis, EDBI, and the Bridge Builder’s Collaborative [Read more…] about Pear Therapeutics raises $50M to develop and market a portfolio of digital therapeutics for mental health